Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada · Delayed Price · Currency is CAD 9.42
-0.11 (-1.15%)
Jul 6, 2026, 10:00 AM EST
Eupraxia Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
A novel, long-acting injectable therapy for EoE shows strong efficacy and safety, with up to 80% clinical remission at six months and sustained benefits for a year. Expansion into related GI conditions and a robust financial runway support continued development and upcoming pivotal trials.
-
Fresh clinical data show rapid, durable remission in EoE with a novel, locally delivered steroid, supported by strong safety and histology results. Well-funded through 2028, the company is expanding into benign esophageal strictures and fibrostenotic Crohn’s, targeting large, underserved GI markets.